Jan 24 (Reuters) - U.S. biotechnology company
Gilead has conceded its first discounts in Germany on
its key hepatitis C drugs Sovaldi and Harvoni, German business
weekly WirtschaftsWoche reported.
The head of Gilead's German operations told the magazine
that discounts from the list price of 60,000 euros ($67,242) per
treatment had been negotiated with four of Germany's statutory
health insurers but declined to give the size of the discounts.
"Thirty-five percent of people with statutory health
insurance are already profiting from the discount agreements,"
Carsten Nowotsch said in an interview to be published on Monday,
adding that more such contracts could follow.
Labels: discounts, drug costs, Germany, insurance, Sovaldi